Introduction
The use of oral anticoagulants has become one of the most common therapies to treat patients suffering from thromboembolic disorders. Warfarin/Acitrom and related coumarins are widely used in thromboembolic prophylaxis. The subtherapeutic and supratherapeutic use of these drugs is associated with an increased risk of clot formation and bleeding, respectively. This is because of the narrow therapeutic index of these anticoagulants.
There is much concern to ensure improvement in the safety of oral anticoagulant therapy, and many efforts have been made for this purpose. However, still, the risks for clotting and bleeding subsequent to oral anticoagulant therapy remain signifi cantly high. [1, 2] Warfarin and Acitrom are two widespread oral anticoagulant drugs that are used to maintain the International Normalized Ratio (INR) within the therapeutic range. However, the dose requirements of these anticoagulants vary between individuals as well as within an individual, depending on the dietary intake or as a result of variations in pharmacokinetics and pharmacodynamics, compliance, etc. [3] In recent years, common genetic variations in vitamin K epoxide reductase (VKOR) have been discovered to signifi cantly influence the oral anticoagulant maintenance dose requirements. Acitrom (or Warfarin) inhibits vitamin K epoxide reductase, [4] specifi cally the VKORC1 subunit, [5, 6] thereby diminishing the available vitamin K and vitamin K hydroquinone in the tissues. 
Materials and Methods

Patients and DNA extraction
The present study was carried out on the patients who had undergone heart valve replacement surgery and were being followed-up for oral-anticoagulant therapy. was extracted from peripheral blood leukocyte pellets using the standard salting-out method. [9] The quality and quantity of DNA was checked by gel electrophoresis and spectrophotometry using the NanoDrop Analyzer (ND-1000) spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The ratio of absorbance at 260
and 280 nm of DNA were between 1.7 and 1.9. The isolated DNA was stored at −70°C.
Genotyping of VKORC1 (-1639G>A, rs9923231) allele by the polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method
G e n o t y p i n g o f V K O R C 1 ( -1 6 3 9 G > A ) w a s performed as described by Sconce et al. [10] Sequences for the forward and reverse primers 
Statistical analysis
The 95% confi dence intervals were calculated using the Confi dence Interval Analysis software version 1.0.
The level of statistical signifi cance was set at P <0.05. All 
Allele and genotype frequencies of VKORC1 alleles in north Indian patients
The VKORC1-1639G>A minor allele frequency in the study population (n = 50) was found to be 22% (95% CI:
15.00-31.07) [ Table 1 ]. Of 50 patients, six patients were homozygous for VKORC1 (-1639 AA) (12%, 95% CI:
5.62-23.80) and 10 patients were heterozygous, having both the alleles (-1639GA) (20%, 95% CI: 11.24-33.04).
Patient characteristics, oral anticoagulation and VKORC1 gene locus
Of the 50 patients, 34 had the VKORC1-1639 GG genotype. This group of patients had six, twenty three and fi ve cases of aortic, mitral and double valve replacement surgery, respectively [ Table 2 
Discussion
The VKORC1-1639G>A minor allele frequency in the study patient group was 22%, which was signifi cantly different from the East Asians as well as the Caucasian populations. [11] The role of genetics in oral anticoagulant dose requirement, in patients with thromboembolic disorders, has been investigated in many previous studies. [12] The daily dose requirement is the highest in the African population, while the white population required intermediate doses and the Asian population required the lowest doses. Lee et al. [7] reported that the mean weight-normalized warfarin dose was lower for the Chinese and the Malays than for the Indians. The highest demand of oral anticoagulant has been observed in patients with the wild type GG genotype, where the enzyme is fully functional. In conclusion, we report the frequency of the important genetic variant The total number of subjects genotyped for the VKORC1-1639 G>A allele is 50 (males = 35 and females = 15); total no. of alleles = 100 VKORC1-1639 G>A in a north Indian patient group that is different from other populations. We also report that the maintenance dose of the oral anticoagulant is dependent on the VKORC1-1639 G>A genotype of the individuals.
Therefore, the genotype should be considered before initiating oral-anticoagulant therapies. The present pilot study was carried out in a relatively smaller number of patients and there is a defi nitive need to replicate it in a larger sample size as well as in various regions and ethnic groups of India before introduction in routine clinical practice.
